Takara Bio Inc.

Since its beginnings as the biomedical business of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.), Takara Bio Inc. has continuously expanded its gene and DNA-related businesses, which have now developed to three business segments. In 1979, the Genetic engineering research business was launched with the sale of the first domestically produced restriction enzymes. This business has now expanded to include a portfolio of genetic engineering research reagents, scientific instruments and contract research services that are essential to biotechnology researchers world-wide. In the AgriBio segment, which was the first to succeed in the artificial cultivation of Bunashimeji mushrooms in 1970, we now offer customers food materials such as kombu “fucoidan,” agar “agaoligo,” Ashitaba “chalcone” and mushroom “polyterpene” whose functionality has been proven through the use of biotechnology. In the Gene medicine segment, we are striving to develop and commercialize cutting-edge medical technologies, such as gene and cell therapies for cancer and AIDS, based on technologies developed and accumulated through the activities of our Genetic engineering research segment. We will establish a stable revenue base in the fields of Genetic engineering research and AgriBio, and by investing revenue from these segments into the Gene medicine segment for the development and commercialization of cell and gene therapy. We have set our mission to develop cutting-edge technologies through the use of our knowledge and technologies accumulated over many years for the benefit of human health around the world.